Thanks for explaining.
Zacks is reporting the ALPN drug is for GvHD.
I suspect that, for those HSCT-TMA patients treated with narso, GvHD is no longer a problem.
We know that Omeros continues providing narso to docs treating HSCT-TMA patients. They provide the drug despite the trial for the indication being over. I have to presume that Omeros is provided with the data on these patients and that is sure to include if they have GVHD or other typical transplant complications.
OMER probably has a load of data on this from the CUP, in addition to the data from the Phase 2 basket TMA trial which is still listed as ongoing on clinicaltrials.gov. Lupus nephritis is included in this basket trial, I believe. I don't recall any guidance about how actively they are recruiting though.